Global Women's Health Diagnostics Market 2017-2021

  • ID: 4240143
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Alere
  • Bio-Rad Laboratories
  • Cepheid
  • F Hoffmann-La Roche
  • Illumina
  • MORE
About Women's Health Diagnostics

Technological advances such as integration of digital technology with diagnostic instrumentation, multiple technologies-based hematology analyzers, and quick monitoring of blood flow in deep tissues with real-time software correlators are boosting the growth of the IVD instruments market. The growing popularity of automation and technological advances have led to new product development user-friendly diagnostic instruments for laboratories and physician offices, as well as home-care settings. Manufacturers are increasingly shifting toward shortened analyzer product cycles with value-added features such as portability of instruments to stay ahead in the market.

The analysts forecast the global women's health diagnostics market to grow at a CAGR of 6.58% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global women's health diagnostics market for 2017-2021. To calculate the market size, the report considers the revenue generated from biomarkers is considered.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Women's Health Diagnostics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Abbott Laboratories
- F. Hoffmann-La Roche
- Hologic
- Siemens Healthineers

Other prominent vendors
- ACON Laboratories
- Alere
- Becton Dickinson (BD)
- bioMérieux
- Bio-Rad Laboratories
- Carl Zeiss Meditec
- Cepheid
- Danaher
- Illumina
- Mindray
- Natera
- Sysmex
- Thermo Fisher Scientific
- Urit Medical

Market drivers
- Reimbursements for human papillomavirus (HPV) tests.
- For a full, detailed list, view the full report

Market challenges
- High cost of mammography equipment.
- For a full, detailed list, view the full report

Market trends
- Increased use of rapid diagnostic testing.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Alere
  • Bio-Rad Laboratories
  • Cepheid
  • F Hoffmann-La Roche
  • Illumina
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 06: Market segmentation by application
  • Cancer
  • UTIs
  • Gynecology and fertility
  • Osteoporosis
PART 07: Market segmentation by end-user
  • Hospitals
  • Clinical diagnostic laboratories
  • ASCs
  • Home-care settings
PART 08: Geographical segmentation
  • Women’s health diagnostics market in Americas
  • Women’s health diagnostics market in EMEA
  • Women’s health diagnostics market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Increased use of rapid diagnostic testing
  • Increasing M&As
  • Increasing demand for home-care monitoring equipment
PART 12: Vendor landscape
  • Competitive scenario
PART 13: Key vendor analysis
  • Abbott Laboratories
  • F. Hoffmann-La Roche
  • Hologic
  • Siemens Healthineers
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Global women's health diagnostics market 2016-2021
Exhibit 02: Global women's health diagnostics market 2016-2021: Overview
Exhibit 03: Global women's health diagnostics market 2016-2021 ($ billions)
Exhibit 04: Five forces analysis
Exhibit 05: Global women's health diagnostics market by application, 2016 (%)
Exhibit 06: Global women's health cancer testing market 2016-2021: Overview
Exhibit 07: Breast cancer: Key takeaways
Exhibit 08: Mammography screening for breast cancer cases (% of women screened)
Exhibit 09: Cervical cancer: Key takeaways
Exhibit 10: Ovarian cancer: Key takeaways
Exhibit 11: Global women's health cancer testing market 2016-2021 ($ billions)
Exhibit 12: Global women's health UTI testing market 2016-2021: Overview
Exhibit 13: Global women's health UTI testing market 2016-2021 ($ billions)
Exhibit 14: UTI testing market: Key takeaways
Exhibit 15: Global women's health gynecology and fertility testing market 2016-2021: Overview
Exhibit 16: Global women's health gynecology and fertility testing market 2016-2021 ($ billions)
Exhibit 17: Gynecology and fertility testing market: Key takeaways
Exhibit 18: Global women's health osteoporosis testing market 2016-2021: Overview
Exhibit 19: Global women's health osteoporosis testing market 2016-2021 ($ billions)
Exhibit 20: Global women's health osteoporosis testing market- Key takeaways
Exhibit 21: Global women's health diagnostics market by end-user (2016)
Exhibit 22: Hospitals in global women's health diagnostic market
Exhibit 23: Clinical diagnostic laboratories in global women's health diagnostic market
Exhibit 24: ASCs in global women's health diagnostic market
Exhibit 25: Home-care settings in global women's health diagnostics market
Exhibit 26: Buying criteria analysis: Global women's health diagnostics market by end-users
Exhibit 27: Smoking rate in women aged 15+ year, 2014 (%)
Exhibit 28: Global women's health diagnostics market by geography 2016 (%)
Exhibit 29: Women's health diagnostics market in Americas 2016-2021: Overview
Exhibit 30: Women's health diagnostic market in Americas 2016-2021 ($ billions)
Exhibit 31: Women's health diagnostics market in EMEA 2016-2021: Overview
Exhibit 32: Women's health diagnostic market in EMEA 2016-2021 ($ billions)
Exhibit 33: Women's health diagnostics market in APAC 2016-2021: Overview
Exhibit 34: Women's health diagnostics market in APAC 2016-2021 ($ billions)
Exhibit 35: Death of women due to breast cancer (%) 2015
Exhibit 36: Survival rate of cervical cancer cases 2013
Exhibit 37: Number of mammography units installed per 1,000,000 inhabitants
Exhibit 38: Advanced catheter portfolio
Exhibit 39: M&As
Exhibit 40: Competitive structure analysis of global women's health diagnostics market 2016
Exhibit 41: Competitive landscape analysis of global women's health diagnostics market 2016
Exhibit 42: Strategic success factors of companies in global women's health diagnostics market
Exhibit 43: Abbott Laboratories: Key highlights
Exhibit 44: Abbott Laboratories: Strength assessment
Exhibit 45: Abbott Laboratories: Strategy assessment
Exhibit 46: Abbott Laboratories: Opportunity assessment
Exhibit 47: F. Hoffmann-La Roche: Key highlights
Exhibit 48: F. Hoffmann-La Roche: Strength assessment
Exhibit 49: F. Hoffmann-La Roche: Strategy assessment
Exhibit 50: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 51: Hologic: Key highlights
Exhibit 52: Hologic: Strategy assessment
Exhibit 53: Hologic: Strategy assessment
Exhibit 54: Hologic: Opportunity assessment
Exhibit 55: Siemens Healthineers: Key highlights
Exhibit 56: Siemens Healthineers: Strength assessment
Exhibit 57: Siemens Healthineers: Strategy assessment
Exhibit 58: Siemens Healthineers: Opportunity assessment
Exhibit 59: Other prominent vendors
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Alere
  • Bio-Rad Laboratories
  • Cepheid
  • F Hoffmann-La Roche
  • Illumina
  • MORE
New Report Released: – Global Women's Health Diagnostics Market 2017-2021

The author of the report recognizes the following companies as the key players in the global women's health diagnostics market: Abbott Laboratories, F. Hoffmann-La Roche, Hologic, and Siemens Healthineers.

Other Prominent Vendors in the market are: ACON Laboratories, Alere, Becton DickBulleted List Propertiesinson, bioMérieux, Bio-Rad Laboratories, Carl Zeiss Meditec, Cepheid, Danaher, Illumina, Mindray, Natera, Sysmex, Thermo Fisher Scientific, and Urit Medical.

Commenting on the report, an analyst from the research team said: “One trend in market is increased use of rapid diagnostic testing. In the past years, advanced techniques and testing platforms for diagnosis of infectious diseases have changed the way pathologists detect the causative organisms of infectious diseases and genetic markers for antimicrobial resistance. The shift from centralized to decentralized POC testing and from single-analyte testing to multiplex testing, along with rapid diagnosis testing options, are demonstrating a significant impact on the practice of medicine and clinical testing.”

According to the report, one driver in market is increasing gynecological diseases in older women. Women who are undergoing menopause show higher prevalence of developing cyst or mass formation in the uterus. It is also common in middle-aged women (40-50 years old). Formation of cysts in the uterus and ovarian cancer are linked to each other. Post-menopausal cysts can increase the risk of ovarian cancer. Ovarian cancer mainly develops in women who are 60 years old or more. The highest incidence of ovarian cancer is reported in the Americas, mainly in the US. According to CDC (2013), about 20,000 women suffer from ovarian cancer every year. In the US, ovarian cancer is the ninth most common disease, as per CDC, accounting for about 3% of the women population in the country.

Further, the report states that one challenges in market is high cost of mammography equipment. There has been an increase in the preference for digital mammography equipment over analog equipment. The equipment cost for digital mammography systems is about 3-5 times the cost of film screen mammography or conventional analog mammography. In addition, the cost of maintenance and image storage in full-field digital mammography systems is high due to digital storage capacity required to accommodate the large file size of digital images. The average cost of digital mammography system is about $200,000-$500,000. The average cost of 3D mammography system is about $430,000, whereas 2D system costs about 30% less than 3D systems.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Abbott Laboratories
  • F Hoffmann-La Roche
  • Hologic
  • Siemens Healthineers
  • ACON Laboratories
  • Alere
  • Becton DickBulleted List Propertiesinson
  • bioMérieux
  • Bio-Rad Laboratories
  • Carl Zeiss Meditec
  • Cepheid
  • Danaher
  • Illumina
  • Mindray
  • Natera
  • Sysmex
  • Thermo Fisher Scientific
  • Urit Medical
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll